Adolescent Schizophrenia Study
Protocol: SITE00000196
Full Title
A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
Description
This study enrolls children with schizophrenia. The purpose of this study is to learn if the study medication (cariprazine) is safe and useful for adolescents ages 13-17.

Your child will be in this study for about 3 months. After your child's first visit, they will come to our office 7 times. During this time your child will undergo various procedures and examinations. Your child will be randomly assigned (like drawing straws) to one of three groups. Two groups will take different amounts of the study drug and one group will take a placebo. A placebo looks like the study drug but has no active ingredients. Neither you, your child, or the study team will know which group your child is in.

Technical Description

The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Compensation: Yes
?
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Eligibility
-Children ages 13-17.
-Diagnosed with schizophrenia.
Age Group: Children
Principal Investigator: STEVEN DUBOVSKY
ClinicalTrials.gov: Open Study
Contact(s)
SEVIE KANDEFER
sk293@buffalo.edu
+1 716-898-4038
Want to Learn More?
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.